“Pfizer has conducted a thorough evaluation of the Irungattukottai and Aurangabad sites and concluded that due to the significant long-term loss of product demand, manufacturing at these sites is not viable,” a spokesperson from Pfizer told The Hindu Business Line.
A spokesperson said affected employees have been notified and will be kept informed about the site exiting process.
The two plants in India were acquired by Pfizer in its acquisition of Hospira.
More articles on pharmacy:
Hospital-owned drug company attracts 12 more health systems
How nurses are becoming integral to pharma marketing: 7 notes
4 tips for managing drug spend from Alameda Health System’s Dr. Yi-Chih Peng
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.